Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
161.20
+1.77 (1.11%)
At close: Nov 20, 2026, 4:00 PM EST
165.79
+4.59 (2.85%)
After-hours: Nov 20, 2026, 7:58 PM EST
Revolution Medicines Stock Forecast
Stock Price Forecast
According to 25 analysts polled by S&P Global, Revolution Medicines stock has a consensus rating of "Strong Buy" and an average price target of $274.68. The average 1-year stock price forecast is 70.40% higher than the current stock price, while the lowest is $179 (+11.04%) and the highest is $350 (+117.12%).
Price Target: $274.68 (+70.40%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Revolution Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 17 | 17 | 17 | 19 | 19 |
| Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 22 | 22 | 22 | 23 | 25 | 25 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bernstein | Bernstein | Hold Maintains $179 | Hold | Maintains | $179 | +11.04% | Nov 20, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $230 | Buy | Maintains | $230 | +42.68% | Nov 20, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $350 | Buy | Reiterates | $350 | +117.12% | Nov 17, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $272 → $247 | Buy | Maintains | $272 → $247 | +53.23% | Nov 13, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $274 | Buy | Maintains | $274 | +69.98% | Nov 13, 2026 |
Financial Forecast
Revenue This Year
613.36M
Revenue Next Year
2.05B
from 613.36M
Increased by 233.69%
EPS This Year
-8.26
from -5.95
EPS Next Year
-3.07
from -8.26
EPS and Forward PE are based on non-GAAP adjusted numbers.